To mitigate the challenges associated with ADC manufacturing, around 70–80% of then therapeutics developers prefer to outsource their operations to contract manufacturing organizations (CMOs), which claim to have the required expertise and experience to leverage their capabilities and yield cost savings opportunities. The report features report features an extensive study of the current...